GoutPhase 3EURELIA2NCT05586971
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
A Phase 3 study testing Tigulixostat and Allopurinol in people with Gout and Hyperuricemia, run by LG Chem at 279 sites in 21 countries.
Trial summary
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Gout, Hyperuricemia, Gout Flare
- What is being tested?
- Tigulixostat and Allopurinol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,202 participants
- Where
- 279 sitesin 21 countries
- Study dates
- 30 Mar 2023to 6 May 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female subjects between the ages of 18 85 years, inclusive.
- Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2015 criteria.
- Subjects who are currently on urate-lowering therapies (ULT) with an sUA level ≥6.0 mg/dL at screening (Visit 1); or subjects who are currently not on ULT with an sUA level ≥7.0 mg/dL at screening (Visit 1). Subjects currently on ULT will undergo washout and must have an sUA level ≥7.0 mg/dL at Visit 3 to be randomized and participate in the study.
- Subjects with a Body Mass Index ≤50 kg/m2 and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 at screening (Visit 1).
Who cannot join
- Subjects with secondary hyperuricemia and enzymatic defects.
- Subjects experiencing an acute gout attack (intense pain, swelling, or/and tenderness in the joint area) within 2 weeks prior to screening (Visit 1).
- Subjects who have received pegloticase to treat gout which has not responded to the usual treatments.
- Subjects who have not been receiving stable doses of drugs known to affect sUA levels for the last 3 weeks prior to screening (Visit 1).
- Subjects with a history of xanthinuria (elevated levels of xanthine in the urine).
Trial locations and contacts
279 sites in 21 countries.
279 sites in 21 countries
United States124 sites
Albuquerque Center for Rheumatology
Albuquerque, New Mexico, 87102
Arthritis & Rheumatic Disease Specialties
Aventura, Florida, 33180
Long Island Regional Arthritis & Osteoporosis Care PC
Babylon, New York, 11702
Velocity Clinical Research
Banning, California, 92220
Inquest Clinical Research
Baytown, Texas, 77521
University of Alabama at Birmingham
Birmingham, Alabama, 35249
Family Care Research, LLC
Boise, Idaho, 83713
Cope Family Medicine/CCT Research
Bountiful, Utah, 84010
American Clinical Trials
Buena Park, California, 90620
Arizona Research Clinic, PLLC
Chandler, Arizona, 85225
Presbyterian Hospital
Charlotte, North Carolina, 28277
IMA Research, Inc.
Chicago, Illinois, 60602
Great Lakes Clinical Trials
Chicago, Illinois, 60640
Clinical Research of West Florida, Inc.
Clearwater, Florida, 33765
PCCR Solutions
Colleyville, Texas, 76034
Centricity Research
Columbus, Georgia, 31904
Herco Medical and Research Center, Inc
Coral Gables, Florida, 33134
Clinical Trials Management, LLC
Covington, Louisiana, 70433
Nouvelle Clinical Research LLC
Cutler Bay, Florida, 33189
Metroplex Clinical Research Center
Dallas, Texas, 75231
DFW Clinical Research
Dallas, Texas, 75234
Alliance for Multispecialty Research, LLC
Daphne, Alabama, 36526
Omega Research Debary, LLC
DeBary, Florida, 32713
MediSphere Medical Research Center, LLC
Evansville, Indiana, 47714
Lillestol Research LLC
Fargo, North Dakota, 58104
Arizona Arthritis & Rheumatology Associates, P.C.
Flagstaff, Arizona, 86001
Healthcare Research Network II, LLC
Flossmoor, Illinois, 60422
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, 33912
Dallas Fort Worth Clinical Research Associates
Fort Worth, Texas, 76177
American Health Network of Indiana, LLC
Franklin, Indiana, 46131
Methodist Physicians Clinic/CCT Research
Fremont, Nebraska, 68025
Arthritis Center of North Georgia
Gainesville, Georgia, 30501
Arizona Arthritis and Rheumatology Research PLLC
Glendale, Arizona, 85306
Triad Clinical Trials, LLC
Greensboro, North Carolina, 27410
Clinical Investigation Specialists, Inc
Gurnee, Illinois, 60031
Hatboro Medical Associates, P.C.
Hatboro, Pennsylvania, 19040
Healthcare Research Network
Hazelwood, Missouri, 63042
Olympus Family Medicine
Hendersonville, North Carolina, 28792
Direct Helpers Research Center
Hialeah, Florida, 33012
Best Quality Research, Inc
Hialeah, Florida, 33016
New Generation Of Medical Research, LLC
Hialeah, Florida, 33016
Vital Pharma Research
Hialeah, Florida, 33016
East West Medical Research Institute
Honolulu, Hawaii, 96814
Pioneer Research Solutions, Inc.
Houston, Texas, 77099
Elite Clinical Research, LLC
Jackson, Mississippi, 39202
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, 64114
Clay-Platte Family Medicine Clinic
Kansas City, Missouri, 64151
New Phase Research
Knoxville, Tennessee, 37909
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, 37920
Accel Research Sites - Lakeland
Lake Mary, Florida, 32746
Accel Research Sites - St. Petersburg- Largo
Lake Mary, Florida, 32746
ARS-Matiland Clinical Research Unit
Lake Mary, Florida, 32746
Shreenath Clinical Service
Lakewood, California, 90805
Healor Primary Care /CCT Research
Las Vegas, Nevada, 89102
Wake Research - CRCN
Las Vegas, Nevada, 89118
Alliance for Multispecialty Research, LLC.
Las Vegas, Nevada, 89119
Alliance for Multispecialty Research, LLC
Lexington, Kentucky, 40509
Lynn Institute of the Ozarks
Little Rock, Arkansas, 72204
Alliance for Multispecialty Research, LLC
Meridian, Idaho, 83642
Arizon Arthritis & Rheumatology Research, PLLC
Mesa, Arizona, 85210
Desert Clinical Research/CCT Research
Mesa, Arizona, 85213
Southwest Rheumatology Research, LLC
Mesquite, Texas, 75150
Clinical Trials Management
Metairie, Louisiana, 70006
Homestead Associates in Research,Inc
Miami, Florida, 33032
Allied Biomedical Research Institute
Miami, Florida, 33155
D&H National Research Centers, Inc.
Miami, Florida, 33155
Ivetmar Medical Group, LLC
Miami, Florida, 33155
Care Research Center Inc
Miami, Florida, 33175
Pharmax Research of South Florida, Inc
Miami, Florida, 33175
Miami Dade Medical Research Institute, LLC
Miami, Florida, 33176
Clinical Site Partners, LLC dba Flourish Research
Miami, Florida, 33186
M&A Medical Centers and Research
Miami, Florida, 33186
Trinity Health Center Medical Arts
Minot, North Dakota, 58701
Montana Medical Research, Inc.
Missoula, Montana, 59808
Alliance for Multispecialty Research, LLC
Mobile, Alabama, 36608
Burke Primary Care
Morganton, North Carolina, 28655
American Health Network of Indiana LLC
Muncie, Indiana, 47304
Syed Research Consultants, LLC
Muscle Shoals, Alabama, 35661
IMA Clinical Research
New York, New York, 10036
Vista Clinical Research, LLC
Newnan, Georgia, 30265
Meridian Clinical Research, LLC
Norfolk, Nebraska, 68701
Olive Branch Family Medical Center
Olive Branch, Mississippi, 38654
HMD Research LLC
Orlando, Florida, 32819
MD Medical Research
Oxon Hill, Maryland, 20745
Arthritis Associates of Northwest Ohio Inc.
Perrysburg, Ohio, 43551
Tristar Clinical Investigations, P.C.
Philadelphia, Pennsylvania, 19114
Elite Clinical Studies, LLC
Phoenix, Arizona, 85018
AIM Trials, LLC
Plano, Texas, 75093
Practice Dr David Headley
Port Gibson, Mississippi, 39150
Meridian Clinical Research, LLC
Portsmouth, Virginia, 23703
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, 91730
Dominion Medical Associates, Inc.
Richmond, Virginia, 23219
Olympus Family Medicine
Salt Lake City, Utah, 84117
Highland Clinical Research
Salt Lake City, Utah, 84124
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229
TriWest Research Associates
San Diego, California, 92108
Rheumatology Center of San Diego
San Diego, California, 92128
Inspire Santa Fe Medical Group
Santa Fe, New Mexico, 87505
Women's & Family Care LLC, dba GTC Research
Shawnee Mission, Kansas, 66218
Syed Research Consultants, LLC
Sheffield, Alabama, 35660
Carolina Research Center, Inc.
Shelby, North Carolina, 28150
South Ogden Family Medicine Clinic
South Ogden, Utah, 84405
Arthritis Northwest, PLLC
Spokane, Washington, 99204
IMA Clinical Research
St Louis, Missouri, 63117
St. Louis Medical Professionals, LLC
St Louis, Missouri, 63119
IMA Clinical Research
St. Petersburg, Florida, 33709
Sugar Lakes Family Practice, PA
Sugar Land, Texas, 77479
Adult Medicine of Lake County, Inc.
Tampa, Florida, 32757
Research Institute of South Florida, Inc.
Tampa, Florida, 33173
Clinical Research of West Florida, Inc.
Tampa, Florida, 33606
Clinical Research Trials of Florida, Inc.
Tampa, Florida, 33607
Nodal Medical Center
Tampa, Florida, 33607
ForCare Clinical Research
Tampa, Florida, 33613
Fiel Family and Sports Medicine/CCT Research
Tempe, Arizona, 85283
DM Clinical Research
Tomball, Texas, 77375
DM Clinical Research
Tomball, Texas, 77377
STAT Research
Vandalia, Ohio, 45377
Versailles Family Medicine
Versailles, Kentucky, 40383
Conquest Research
Vestal, New York, 13850
Integrated Clinical Trial Services Inc.
West Des Moines, Iowa, 50265
Velocity Clinical Research, Salt Lake City
West Jordan, Utah, 84088
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67207
Clinical Site Partners LLC dba CSP Orlando
Winter Park, Florida, 32789
Conquest Research
Winter Park, Florida, 32789
Philippines14 sites
Angeles University Foundation Medical Center
Angeles, 2009
Baguio General Hospital and Medical Center
Baguio City, 2600
Cebu Doctors' University Hospital
Cebu, 6000
De la Salle Medical and Health Sciences Institute
Dasmariñas, 4114
Davao Doctors Hospital
Davao City, 8000
Iloilo Doctors' Hospital Inc
Iloilo City, 5000
St. Paul's Hospital of Iloilo
Iloilo City, 5000
Lipa Medix Medical Center
Lipa, 4217
Ospital ng Makati
Makati, 1210
Makati Medical Center
Makati, 1229
Manila Doctors Hospital
Manila, 1000
Medical Center Manila
Manila, 1000
University of the Philippines - Philippine General Hospital
Manila, 1000
Chinese General Hospital and Medical Center
Manila, 1014
Poland13 sites
ClinicMed Daniluk, Nowak Spdtka komandytowa
Bialystok, 15-879
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
Elblag, 82-300
Malopolskie Centrum Kliniczne
Krakow, 30-149
Pratia MCM Krakow
Krakow, 30-727
Centrum Medyczne PROMED
Krakow, 31-513
SOMED CR
Lodz, 90-368
Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
Lublin, 20-607
ETYKA - Ośrodek Badań Klinicznych
Olsztyn, 10-117
FutureMeds Warszawa Centrum
Warsaw, 00-215
MICS Centrum Medyczne Warszawa
Warsaw, 00-874
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
Warsaw, 02-637
FutureMeds Targéwek
Warsaw, 03-291
Reum-Medica S.C. Bozena Kowalewska, Marek Zawadzki
Wroclaw, 50-244
Argentina12 sites
Hospital Universitario Austral
Buenos Aires, B1635
Instituto de Investigaciones Clinicas San Nicolás
Buenos Aires, B2900
Centro Médico Reumatologico - Organizacion Medica de Investigacion S.A. (OMI)
Buenos Aires, C1015
Aprillus Asistencia e Investigacion Clinica
Buenos Aires, C1406A
Centro Privado de Medicina Familiar
Buenos Aires, C1417EYG
Clinica Adventista Belgrano
Buenos Aires, C1430EGF
Instituto de Investigaciones Clinicas Cordoba
Córdoba, X5000AAW
Centro Integral De Dianogostico por Imagenes Marchegiani (CIDIM)
Córdoba, X5000AVE
Instituto Reumatologico Strusberg
Córdoba, X5000EOC
Clinica Privada Velez Sarsfield (CPVS)
Córdoba, X5016LIG
Centro de Investigaciones Médicas Tucuman
San Miguel de Tucumán, T4000
Instituto CAICI (Instituto Centralizado de Asistencia e Investigacion Clinica Integral)
Santa Fe, S2000PBJ
Spain12 sites
Hospital Universitario de A Coruña
A Coruña, 15006
HM Hospital Nuestra Señora de la Esperanza
A Coruña, 15705
Hospital Clinico Universitario de Santiago de Compostela (CHUS)
A Coruña, 15706
Hospital Sanitas CIMA
Barcelona, 08034
Hospital de La Santa Creu i Sant Pau
Barcelona, 08041
Hospital de Bellvitge
Barcelona, 08907
Hospital Universitario Reina Sofia
Córdoba, 14004
Hospital Universitario Infanta Leonor
Madrid, 28031
Hospital Universitario La Paz
Madrid, 28046
Clinica Gaias Santiago
Santiago de Compostela, 15702
Hospital Quirónsalud Sagrado Corazón
Seville, 41013
Hospital do Meixoeiro
Vigo, 36214
New Zealand10 sites
Southern Clinical Trials Totara
Auckland, 0600
PCRN Silverdale Medical Centre
Auckland, 0932
Aotearoa Clinical Trials
Auckland, 2025
Pacific Clinical Research Network (PCRN) Clinical Trials
Christchurch, 8013
Lakeland Clinical Trials Waikato
Hamilton, 3200
Waikato Hospital
Hamilton, 3204
Southern Clinical Trials Tasman
Nelson, 7011
Pacific Clinical Research Network (PCRN) - Rotorua
Rotorua, 3010
Lakeland Clinical Trials Wellington
Wellington, 5018
Wellington Regional Hospital
Wellington, 6021
South Korea9 sites
Pusan National University Hospital
Busan, 49241
Keimyung University Dongsan hospital
Daegu, 41931
Chonnam National University Hospital
Gwangju, 61469
Jeju National University Hospital
Jeju City, 63241
Kyunghee University Hospital
Seoul, 02447
Hanyang University Hospital
Seoul, 04763
Asan Medical Center
Seoul, 05505
Gangnam Severance Hospital
Seoul, 06273
Uijeongbu Eulji Medical Cen
Uijeongbu-si, 11759
Brazil8 sites
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, 30150-221
CETI - Centro de Estudos em Terapias Inovadoras
Curitiba, 80030-110
EDUMED - Educação em Saúde S/S Ltda
Curitiba, 80440-080
LMK Serviços Médicos Sociedade Simples
Curitiba, 90480-000
CMIP-Centro Mineiro de Pesquisa
Juiz de Fora, 36010-570
Hospital de Clínicas de Porto Alegre
Porto Alegre, 90035-903
SER - Serviços Especializados em Reumatologia da Bahia
Salvador, 40150-150
Clinica Medica Bonfiflioli Ltda
São Paulo, 13015-001
Bulgaria8 sites
University Multiprofile Hospital for Active Treatment Plovdiv "Eurohospital" Ltd
Plovdiv, 4004
Mbal Lyulin EAD
Sofia, 1336
Medical Center Excelsior OOD
Sofia, 1407
DCC Fokus-5 Lzip OOD
Sofia, 1463
Medical Center-N.I. Pirogov EOOD
Sofia, 1606
Military medical academy
Sofia, 1606
Acibadem City Clinic Diagnostic And Consultation Center Ltd
Sofia, 1784
Medical Center Synexus Sofia EOOD
Sofia, 1784
Georgia8 sites
"LJ Clinic" LTD
Kutaisi, 4600
Aleksandre Aladashvili Clinic LLC
Tbilisi, 0102
LTD "Israeli-Georgian Medical Research Clinic Helsicore"
Tbilisi, 0112
Cardioclinic - Digomi Medical Center
Tbilisi, 0159
JSC "Evex Hospitals"
Tbilisi, 0159
Tbilisi Heart and Vascular Clinic
Tbilisi, 0159
LTD MediClub Georgia
Tbilisi, 0160
Multiprofile Clinic Consilium Medula LTD
Tbilisi, 0186
Germany8 sites
Emovis GmbH
Berlin, 10629
Gemeinschaftspraxis Dres. T. und N. Jung
Deggingen, 73326
Klinische Forschung Dresden GmbH
Dresden, 01069
Medizentrum Essen Borbeck
Essen, 45355
Velocity Clincial Research Hamburg GmbH
Hamburg, 22143
Praxis für klinische Studien
Hamburg, 22415
Klinische Forschung Karlsruhe GmbH
Karlsruhe, 76137
Klinische Forschung Schwerin GmbH
Schwerin, 19055
Malaysia8 sites
Hospital Selayang
Batu Caves, 68100
University Malaya Medical Centre
Kuala Lumpur, 50603
Klinik Kesihatan Kuang Lumpur
Kuala Lumpur, 53200
Hospital Umum Sarawak
Kuching, 93586
Klinik Kesihatan Masjid Tanah
Masjid Tanah, 78300
Hospital Miri
Miri, 98000
Klinik Kesihatan Kuang
Rawang, 48050
Hospital Seri Manjung
Seri Manjung, 32040
Thailand8 sites
King Chulalongkorn Memorial Hospital
Bangkok, 10330
Phramongkutklao Hospital
Bangkok, 10330
Rajavithi Hospital
Bangkok, 10400
Ramathibodi Hospital
Bangkok, 10400
Siriraj Hospital
Bangkok, 10700
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, 50200
Thammasat University Hospital
Khlong Luang, 12120
Songklanagarind Hospital
Songkhla, 90110
France6 sites
CHU De Bordeaux
Bordeaux, 33076
Hôpital Saint Philibert
Lomme, 59160
Hôpital Edourad Herriot
Lyon, 69003
Hôpital Lapeyronie
Montpellier, 34295
Centre Hospitalier Regional D'Orleans
Orléans, 45067
CHU Hôpitaux De Rouen
Rouen, 76031
Taiwan6 sites
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 83301
Chung Shan Medical University Hospital
Taichung, 40201
China Medical University Hospital
Taichung, 404327
Taichung Veterans General Hospital
Taichung, 40705
Chi Mei Medical Center
Tainan, 71004
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital
Taoyuan City, 33305
Australia5 sites
Emeritus Research (Melbourne)
Camberwell, 3124
Holdsworth House Medical Practice
Darlinghurst, 2010
Griffith University Clinical Trial Unit
Southport, 4111
Emeritus Research (Sydney)
Sydney, 2019
The Queen Elizabeth Hospital
Woodville South, 5011
Czechia5 sites
MUDr. Michaela Blahova, revmatologicka ambulance s.r.o.
Brno, 602 00
REVMACLINIC s.r.o.
Brno, 611 41
L.K.N Arthrocentrum
Hlučín, 748 01
Revmatologicky ustav
New Town, 128 50
MEDICAL PLUS s.r.o.
Uherské Hradiště, 686 01
Italy5 sites
Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo Alessandria
Alessandria, 15121
IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, 20157
AOU Policlinico Paolo Giaccone
Palermo, 90127
AUSL di Reggio Emilia, Arcispedale Santa Maria Nuova-IRCCS
Reggio Emilia, 42123
Azienda Ospedaliera Universitaria Integrata Verona
Verona, 37134
Colombia4 sites
Centro de Investigacion en Reumatología y Especialidades Médicas S.A.S (CIREEM S.A.S)
Bogotá, 110221
Servimed S.A.S.
Bucaramanga, 680003
IPS Medicos Internistas de Caldas SAS
Manizales, 170004
Healthy Medical Center SAS
Zipaquirá, 250252
Belgium3 sites
ReumaClinic
Genk, 3600
CHU de Liège
Liège, 4000
CHU HELORA - Hôpital de Mons - Site Kenedy
Mons, 7000
Lithuania3 sites
Hospital of Lithuanian University of Health Sciences Kauno klinikos
Kaunas, 50161
Kaunas City Polyclinic, Dainava Outpatient Clinic
Kaunas, 51270
Klaipeda University Hospital
Klaipėda, 92288
About this study
Official title: A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Being tested
- Tigulixostat, Allopurinol, Placebo
- Keywords
- Gout, Hyperuricemia, Xanthine Oxidase Inhibitor
- Medical subject headings
- Gout, Hyperuricemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TigulixostatDrug
Also called LC350189
Xanthine Oxidase Inhibitor
AllopurinolDrug
Xanthine Oxidase Inhibitor
PlaceboDrug
Matching placebo
| Study group | Role | What they receive |
|---|---|---|
| Tigulixostat 100mg | Experimental | Tigulixostat 100mg, Once a day (QD) for up to 12 months Receives: Drug: Tigulixostat |
| Tigulixostat 200mg | Experimental | Tigulixostat 200mg, Once a day (QD) for up to 12 months Receives: Drug: Tigulixostat |
| Tigulixostat 300mg | Experimental | Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months Receives: Drug: Tigulixostat |
| Titrated allopurinol (100-800mg) | Active comparator | Allopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg. Receives: Drug: Allopurinol |
| Placebo | Placebo comparator | Placebo, three times a day (TID) for up to 6 months. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Measured: Up to Month 6
Secondary outcomes (4)
The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Measured: Up to Month 6
Proportion of subjects with at least one gout flare from Month 6 to Month 12.
Gout flare (intense pain, swelling, or/and tenderness in the joint area) will be assessed from baseline up to 12 months
Measured: From Month 6 to Month 12
Proportion of subjects with complete resolution of ≥1 target tophus by Month 12
Tophi will be measured by independent central blind reader
Measured: Up to Month 12
Incidence rate of adverse event
Safety assessment
Measured: Up to Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2022
- Study start30 Mar 2023
- Primary completion6 May 2025
- Study completion6 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 2,202 participants (actual)
Sponsor and investigators
- Lead sponsor
- LG Chem
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Hyungjin Cho, MD, Study director, LG Chem
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05586971
- Sponsor's protocol ID
- LG-GDCL010
- Acronym
- EURELIA2
- Status last verified
- Jul 2025
- First submitted
- 16 Oct 2022
- Last updated
- 22 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, Hariri A, Lee Y, Jang Y, Han S, Choi HK. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025 Apr;151:107843. doi: 10.1016/j.cct.2025.107843. Epub 2025 Feb 8.
PubMed 39929260
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
- ClinicalTrials.gov ID
- NCT05586971
- Acronym / sponsor ID
- EURELIA2 / LG-GDCL010
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Keywords
- Gout, Hyperuricemia, Xanthine Oxidase Inhibitor
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,202 participants (actual)
- Lead sponsor
- LG ChemIndustry (pharma, biotech, devices)
- Study start
- 30 Mar 2023 (actual)
- Primary completion
- 6 May 2025 (actual)
- Study completion
- 6 May 2025 (actual)
- First posted
- 19 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Tigulixostat 100mg | Experimental | Drug: TigulixostatTigulixostat 100mg, Once a day (QD) for up to 12 months |
| Tigulixostat 200mg | Experimental | Drug: TigulixostatTigulixostat 200mg, Once a day (QD) for up to 12 months |
| Tigulixostat 300mg | Experimental | Drug: TigulixostatTigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months |
| Titrated allopurinol (100-800mg) | Active comparator | Drug: AllopurinolAllopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg. |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo, three times a day (TID) for up to 6 months. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female subjects between the ages of 18 85 years, inclusive.
- Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2015 criteria.
- Subjects who are currently on urate-lowering therapies (ULT) with an sUA level ≥6.0 mg/dL at screening (Visit 1); or subjects who are currently not on ULT with an sUA level ≥7.0 mg/dL at screening (Visit 1). Subjects currently on ULT will undergo washout and must have an sUA level ≥7.0 mg/dL at Visit 3 to be randomized and participate in the study.
- Subjects with a Body Mass Index ≤50 kg/m2 and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 at screening (Visit 1).
Key exclusion criteria (5 listed)
- Subjects with secondary hyperuricemia and enzymatic defects.
- Subjects experiencing an acute gout attack (intense pain, swelling, or/and tenderness in the joint area) within 2 weeks prior to screening (Visit 1).
- Subjects who have received pegloticase to treat gout which has not responded to the usual treatments.
- Subjects who have not been receiving stable doses of drugs known to affect sUA levels for the last 3 weeks prior to screening (Visit 1).
- Subjects with a history of xanthinuria (elevated levels of xanthine in the urine).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TigulixostatAlso: LC350189Xanthine Oxidase Inhibitor | Drug | Tigulixostat 100mg, Tigulixostat 200mg, Tigulixostat 300mg |
| AllopurinolXanthine Oxidase Inhibitor | Drug | Titrated allopurinol (100-800mg) |
| PlaceboMatching placebo | Drug | Placebo |
Primary outcome
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6
Time frame: Up to Month 6
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
4 secondary outcomes
The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6
Time frame: Up to Month 6
Proportion of subjects with at least one gout flare from Month 6 to Month 12.
Time frame: From Month 6 to Month 12
Proportion of subjects with complete resolution of ≥1 target tophus by Month 12
Time frame: Up to Month 12
Incidence rate of adverse event
Time frame: Up to Month 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
- Derived from this study: PubMed 39929260Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, Hariri A, Lee Y, Jang Y, Han S, Choi HK. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025 Apr;151:107843. doi: 10.1016/j.cct.2025.107843. Epub 2025 Feb 8.
- Individual participant dataSharing planned: No
Related trials for Gout
RecruitingPhase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Enrolling by invitation
The Remote Monitoring of Gout Study
Gout Initiating Urate-loweringUrate-lowering Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hyungjin Cho, MD study director
LG Chem
279 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tigulixostat and Allopurinol in people with Gout and Hyperuricemia, run by LG Chem at 279 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 279 sites in United States, Philippines, Poland, Argentina, Spain and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6 (time frame: Up to Month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05586971, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.